Company: SUPN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0001356576-25-000017
Chunk: 212

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 8
Chunk 212
---
 assets686,070 493,113 Long-term marketable securities— 16,617 Property and equipment, net11,545 13,530 Intangible assets, net521,912 599,889 Goodwill117,019 117,019 Other assets31,527 37,505 Total assets$1,368,073 $1,277,673 Liabilities and stockholders’ equityCurrent liabilitiesAccounts payable and accrued liabilities$76,352 $79,569 Accrued product returns and rebates168,705 154,274 Contingent consideration, current portion47,340 52,070 Other current liabilities— 4,283 Total current liabilities292,397 290,196 Contingent consideration, long-term— 1,380 Operating lease liabilities, long-term27,382 33,196 Deferred income tax liabilities, net4,961 24,963 Other liabilities7,600 6,422 Total liabilities332,340 356,157 Commitments and contingencies (Note 16)Stockholders’ equityCommon stock, $0.001 par value; 130,000,000 shares authorized; 55,743,095 and 54,723,356 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively56 55 Additional paid-in capital479,440 439,493 Accumulated other comprehensive loss, net of tax(189)(593)Retained earnings556,426 482,561 Total stockholders’ equity1,035,733 921,516 Total liabilities and stockholders’ equity$1,368,073 $1,277,673 

See accompanying notes.

92

Supernus Pharmaceuticals, Inc.

Consolidated Statements of Earnings

(in thousands, except share and per share data) Year Ended December 31, 202420232022RevenuesNet product sales$637,696 $573,933 $649,432 Royalty, licensing and other revenues24,121 33,588 17,806 Total revenues661,817 607,521 667,238 Costs and expensesCost of goods sold(a)77,906 83,779 87,221 Research and development108,796 91,593 74,552 Selling, general and administrative321,582 336,